phrma logo

PhRMA

PhRMA Sites

Login

Explore Member-Only Resources

Access exclusive advocacy, policy, and research materials through the member site.

Login now

About

About

Our Agenda

Our Agenda

Policy Issues

We believe that patients should have access to innovative medicines.

Learn More

Innovation Ecosystem

Intellectual Property

Research & Development

Future of Medicine

Government Price Setting

International

Innovation Ecosystem

Patient Access & Affordability

PBMs & Middlemen

Hospitals and 340B

Insurance Coverage

Cost of Medicines

Medicare & Medicaid

Patient Access & Affordability

Resources

Our mission is to conduct effective advocacy for public policies that encourage the discovery of important, new medicines for patients by biopharmaceutical research companies.

Learn More

Resources

Resources

Newsroom

Newsroom

Blog

Blog

America's Medicines

PhRMA Foundation

PhRMA Foundation Logo

Voters for Cures

VotersForCures.org Logo

Working for Cures

workersforcures.org logo

This is Innovation

Innovation.org logo

View More

Search in PhRMA

Find resources, news, and articles related to policy issues and scientific innovation.

What are you looking for?

Most Recent

Policy Paper

Press

Blog

Report

Fact Sheet

Event

Resource

Pages

Leader

Author

Comment

not used title

not used title

Did you know Medicaid and the Children’s Health Insurance Program provide health coverage for more than 83 million vulnerable Americans, including children and their parents, pregnant women, the elderly and people living with disabilities? This state-federal partnership provides Americans across the country with access to needed medications with low to no cost sharing. Here are three facts about Medicaid that you may not know. 

1. Manufacturers pay statutory rebates to help ensure patients have affordable access to medicines. Manufacturers work with the federal government to provide significant discounts on medicines to ensure people with Medicaid have access to lifesaving and life-altering medicines. Under the Medicaid Drug Rebate program, manufacturers pay steep statutory rebates which provide the “best price” among payers to states for medicines. In exchange, Medicaid is required to cover generally all “medically accepted indications” of covered outpatient medicines. Rebates from manufacturers increase as Medicaid enrollment grows, helping offset the costs to states providing access to prescription medicines. For example, in 2019 manufacturers paid Medicaid rebates totaling $36.1 billion to states and the federal government. 

012522_PhRMA_MedicaidChartPack_G1

2. Spending on retail medicines is a small share of total Medicaid spending, in large part because of the support manufacturers provide through rebates. Retail medicines account for just over 4% on average. Comparatively, administrative costs represent roughly 6% of total Medicaid budgets on average and about 54% of Medicaid spending is on hospital and nursing facilities, which could include some medicines provided in the hospital.

For example, in 2018 net Medicaid retail medicine spending (including on brand medicines and generics) was $33.4 billion, while total Medicaid spending was $597.4 billion. Even projections for 2028 suggest Medicaid retail medicine spending will continue to be a small share of total Medicaid spending. 

012522_PhRMA_MedicaidChartPack_G2

3. Some states are limiting access to brand medicines in Medicaid despite the agreement between manufacturers and states to provide rebates in exchange for robust prescription medicine coverage. All states currently provide prescription medicine coverage but may rely on preferred drug lists to control which medicine patients can get. Other states limit how many prescriptions patients can fill each month.

This is especially critical because Medicaid patients, compared to those with other types of insurance, often have more complex and chronic health conditions that often require access to a broad range of medicines. Policies that limit access to medicines in Medicaid, such as restrictions on what medicines are available and one-size-fits all value assessments on medicines, could put millions of people at risk, lead to poorer health outcomes for already vulnerable populations, and contribute to higher costs across the health care system.

012522_PhRMA_MedicaidChartPack_G3

Medicaid is an important program, providing coverage for millions of Americans. Access restrictions drive up costs for patients, which is counter to the goals of the Medicaid program. Policymakers should take steps to protect patient access to medicines through Medicaid.   

Learn more about access to medicines through Medicaid. 

Jasmine Gossett

is a Director of Public Affairs at PhRMA.

Jasmine Gossett

Delivering breakthroughs and lower costs for patients

September 8, 2025

The hidden cost of 340B: A multi-billion-dollar burden on taxpayers and Medicaid

July 14, 2025

Ensuring access to affordable medicines for patients through Medicaid

April 28, 2025

Biopharmaceutical innovation for a healthier America: PhRMA releases new innovation report

February 21, 2025

New policy agenda charts solutions for a healthier America

February 20, 2025

A successful PhRMA Forum highlights our commitment to a healthier America

February 20, 2025

CMS, don’t fall behind the rest of the medical community on obesity

February 14, 2025

The real cost of denying access to medicines in Medicaid

February 12, 2025

Reimagining patient access through meaningful policy reform

November 5, 2024

New PES survey: Out-of-pocket costs lead key health care priorities ahead of the November election

October 30, 2024

Don’t put the government between patients and their medicines

August 7, 2024

Medicaid by the numbers

July 30, 2024

WTAS: Voters voice concerns about PBM abuses, call on policymakers to act

July 19, 2024

The IRA could lead to higher out-of-pocket costs for 3.5 million Medicare patients in 2026

June 25, 2024

Ongoing federal probes shed light on PBM and insurer practices

May 20, 2024

WTAS: The consequences of consolidation and vertical integration

May 6, 2024

Providing affordable access to medicines in Medicaid

April 30, 2024

Insurance data: PBM reform has no material impact on premiums

April 24, 2024

ICYMI: Voter priorities this election season

April 18, 2024

Four years later, Maryland board still hasn’t delivered for patients

February 12, 2024

Setting the Record Straight: Comparing U.S. drug prices to those in foreign countries hurts patients

February 7, 2024

When it comes to the future of innovation, the ball is in policymakers’ court

January 22, 2024

ICYMI: When middlemen get in the way, it’s the patients who lose

December 5, 2023

Increased use of prior authorization in Medicaid is blocking access for patients

November 28, 2023

The IRA’s pill penalty threatens the future of oncology R&D

November 16, 2023

ICYMI: WSJ — Same Drug, Two Prices: Why the Higher Price Prevails

November 15, 2023

One year to Election Day: Four voter priorities to watch

November 6, 2023

ICYMI: Scott LaGanga and Matt Salo deliver a State of the Industry Report

October 25, 2023

ICYMI: Government watchdog report finds patients in Medicare Part D paid billions more for medicines than insurers and PBMs

September 28, 2023

Word of the Month: AMR

September 27, 2023

Medicare Prescription Payment Plan will benefit patients if implemented correctly

September 21, 2023

New analysis shows PBMs use fees as a profit center

September 18, 2023

New PhRMA ad exposes yet another way PBMs get between patients and their medicines

September 5, 2023

Manufacturers provided $42 billion in Medicaid discounts in 2021 alone

August 10, 2023

CMS should rethink proposed changes to the Medicaid Drug Rebate Program | PhRMA

August 1, 2023

Three things to know from the latest Patient Experience Survey

July 20, 2023

More than 60 researchers ask Congress to support innovation

June 26, 2023

ICYMI: PBM exec admits choosing profits over patients

June 2, 2023

New calculator demonstrates how improved adherence to anti-diabetic medicines can benefit people in Medicaid

May 25, 2023

4 key facts on medicine prices and spending

May 9, 2023

4 Things to know about PhRMA’s new 50-state poll

May 4, 2023

Americans want state policymakers to lower out-of-pocket costs

May 1, 2023

Policies need to address the growing threat of antimicrobial resistance

April 28, 2023

Three facts about health care spending

April 25, 2023

AHIP’s latest misinformation campaign & what it’s trying to hide

April 24, 2023

New global analysis shows patient access challenges around the world

April 12, 2023

States can support access to medicine as COVID-19 Public Health Emergency ends

April 5, 2023

Arkansas puts patients first with new share the savings law

April 4, 2023

Key Trends: Patient experience data reveal how insurers and middlemen impose barriers in health care

March 29, 2023

Holding pharmacy benefit managers accountable

February 23, 2023

Stopping pharmacy benefit managers from “gaming the system”

February 22, 2023

Senate hearing to examine bipartisan reforms to rein in middlemen

February 16, 2023

Minnesota lawmakers are letting PBMs off the hook, and threatening patients’ access to medicines

January 31, 2023

ICYMI: PhRMA kicks off the year at the 2023 J.P. Morgan Health Care Conference

January 19, 2023

Study finds hepatitis C cure saved Medicaid $15 billion

January 5, 2023

ICYMI: PhRMA COO Lori Reilly speaks about the health care agenda for the next Congress

December 9, 2022

In their own words: Financial barriers exacerbate access challenges for insured Americans

December 8, 2022

Putting Delaware patients first: Protecting Patient Assistance Programs

November 22, 2022

New data show how insurers and middlemen shift Rx costs onto patients

November 16, 2022

In their own words: Insured Americans struggle to navigate complex coverage

October 26, 2022

Many seniors are paying more for Part D medicines than their insurer

October 18, 2022

New comments outline ways to protect patients from health plans and PBMs who profit from patient assistance

October 7, 2022

Busting 3 Myths About Copay Coupons

October 5, 2022

Mental Illness Awareness Week – A time for reflection

October 3, 2022

A key fact the White House is reluctant to admit

September 27, 2022

A key fact the White House is reluctant to admit

September 27, 2022

Navigating the patient experience: Burdens and barriers standing between patients and their care

September 12, 2022

Making coupons count for patients at the pharmacy counter

August 25, 2022

New survey: Voters seriously concerned about fine print in reconciliation bill

August 12, 2022

Making coupons count for patients with HIV

August 8, 2022

Myth vs. Fact: The Senate’s latest price setting proposal

August 5, 2022

The Senate’s latest price setting proposal will undermine U.S. economic growth

August 3, 2022

Celebrating Medicare’s 57th anniversary

August 2, 2022

New analysis finds deeper impact of drug pricing bill on biopharmaceutical researchers

August 1, 2022

The Senate’s latest price setting proposal will undermine: Our health care system

July 28, 2022

The Senate’s latest price setting proposal will undermine: American medical innovation

July 27, 2022

The Senate’s latest price setting proposal will undermine: Patient access to medicines

July 26, 2022

Survey Says: Prescription drug prices are not fueling inflation concerns for Americans

July 22, 2022

The Patient Perspective: Government price-setting harms patients

July 22, 2022

Putting patients first at the state level — A conversation with Mark Reisenauer, President of Astellas Pharma US

July 14, 2022

Polling continues to show voters reject so-called Medicare “negotiation” once they learn about consequences for patients

July 12, 2022

By the Numbers: Patients lose when the government sets prices

July 8, 2022

Patients win as West Virginia implements first-in-nation share the savings policy

July 8, 2022

3 things voters are concerned about when it comes to their health care coverage

July 7, 2022

Copay assistance is a lifeline for patients. So why are insurers blocking it?

June 29, 2022

Patients support state action requiring PBMs and insurers to share savings and cap costs for medicines

June 16, 2022

New poll shows voters sounding the alarm on health insurance companies and PBMs

June 6, 2022

PhRMA warns of the growing influence of middlemen over patient access and out-of-pocket costs for patients

May 31, 2022

ICYMI: PhRMA COO Lori Reilly spotlights efforts to improve health care in 2022 and beyond

May 9, 2022

Study finds insurance barriers disproportionately burden patients with chronic illness

May 4, 2022

Three charts show how the Medicare Part D program could be improved to work better for seniors and people with disabilities

April 27, 2022

What’s really happening when it comes to prescription drug costs

April 27, 2022

5 public opinion polling trends to watch

April 22, 2022

Analysis: States can help patients save nearly $1,000 annually on their medicines

April 21, 2022

New analysis confirms hospitals markup prices for oncology therapies

April 21, 2022

How standardized plans can improve patients’ access to medicines

April 18, 2022

The patient experience: Uncovering the barriers to care for insured Americans

March 28, 2022

Correcting the record: Putting medicine costs and spending in context

March 24, 2022

Sharing rebates can save Americans with diabetes 500 each year and improve adherence

March 16, 2022

Veterans Affairs 101: Three charts show how the VA system differs from Medicare

March 11, 2022

If drug prices are growing below the rate of inflation, why are patients still feeling the sting at the pharmacy?

March 8, 2022

The patient experience: Insurance barriers continue to impede access to health care, especially among the country’s underserved

February 28, 2022

Government price setting leaves behind families counting on new medicines

February 23, 2022

PhRMA submits comments urging CMS to withdraw coverage proposal

February 11, 2022

Government price setting won’t stop insurers from shifting costs to patients

February 2, 2022

New comments outline ways to counteract cost-shifting insurance trends

January 28, 2022

Patients need to pay less for their medicines. States can help.

January 26, 2022

It’s a new year, but sadly Congress is still pursuing flawed price setting policies

January 25, 2022

New poll of all 50 states and 435 Congressional Districts shows perils of so-called Medicare “negotiation”

January 25, 2022

CBO reaffirms our innovation ecosystem leads to improved lives, long-term savings

January 21, 2022

New study finds more than half of brand medicine spending goes to the supply chain and others

January 7, 2022

Making medicines more affordable: Preserving safety-net programs like 340B

December 17, 2021

Post-approval research save lives. Why is Congress trying disincentivize it?

December 17, 2021

A price control by any other name would still put patients at risk and threaten innovation

December 9, 2021

Making medicines more affordable: Making insurance work like insurance

December 8, 2021

3 things to know about the importance of post-approval research and development

December 6, 2021

Navigating the patient experience in the time of COVID-19

December 6, 2021

Insurance design barriers can impact patient adherence and can lead to poor health outcomes

November 23, 2021

What is missing in the current drug pricing plan

November 23, 2021

ICYMI: PhRMA CEO speaks at STAT Summit about government price setting

November 19, 2021

Making medicines more affordable: Sharing savings at the pharmacy counter

November 19, 2021

Three things to know about so-called Medicare negotiation polling

November 18, 2021

In the current health care debate, Congress has lost sight of what matters to U.S. voters

November 15, 2021

Making medicines more affordable: Modernizing Medicare

November 11, 2021

Making Medicines More Affordable: Making coupons count

November 5, 2021

What they are saying: Government price setting for medicines is not the answer

November 4, 2021

Four things to know from IQVIAs latest report

October 29, 2021

The patient experience: Insurance design hurdles lead to access issues for too many Americans

October 28, 2021

The patient experience: Out-of-pocket costs are driving patients affordability and access challenges

October 19, 2021

ICYMI: New study confirms policies like H.R. 3 could significantly reduce drug development

October 18, 2021

New poll shows Americans reject Medicare negotiation once they learn more about the policy

October 15, 2021

New report shows 3 in 10 Americans that have insurance still face a financial barrier to care

October 7, 2021

Industry leaders discuss the impact of the drug pricing debate

September 23, 2021

Five reasons tying VA prices to Medicare Part D misses the mark

September 22, 2021

PhRMA releases 2021 industry profile

September 20, 2021

America’s biopharmaceutical companies to Congress: Government “negotiation” is the wrong approach

September 15, 2021

ICYMI: Event spotlights how we can make Medicare work better for patients

August 4, 2021

The future of the rebate rule: Will policymakers stand with patients?

August 2, 2021

Celebrating Medicare’s 56th anniversary

July 30, 2021

Government “negotiation” could have devastating consequences for Medicare enrollees

July 23, 2021

Protecting Medicare from government interference

July 21, 2021

3 factors impacting medication adherence for patients with diabetes

July 20, 2021

Data shows voters strongly support protecting access to their medicines

July 15, 2021

Medicare “negotiation” proposals threaten Americans’ access to medicines

June 30, 2021

Building a better health care system: A conversation with Mark Reisenauer, President of Astellas US

June 23, 2021

New reports shed light on key facts about medicines and affordability

June 8, 2021

Out-of-pocket trends in Medicare Part D show rising costs for seniors

May 24, 2021

Study finds nearly half of payers believe innovative contracts can lead to lower patient out-of-pocket costs

May 17, 2021

Four solutions Americans support to make health care more affordable

May 13, 2021

The FDA Office of Minority Health and Health Equity: Working to advance health equity through diversity in research

May 12, 2021

H.R. 3 threatens access to medicines, future innovation and American jobs

May 4, 2021

New data from insurers show detriments of copay accumulator adjustment programs

April 28, 2021

West Virginia becomes the first state to lower patient costs by sharing the savings

April 20, 2021

Our three-part approach to build a better health care system

April 13, 2021

Nearly 40% of commercially insured patients face half their annual out-of-pocket expenses from just one health care encounter

March 2, 2021

Top five issues voters want addressed in the administration’s first 100 days

February 18, 2021

Insurers shift medicine costs to patients with severe chronic illnesses

February 1, 2021

Tennessee’s Medicaid demonstration fails patients

February 1, 2021

The latest misleading “poll” on drug pricing

January 28, 2021

Election insights: Common ground areas to address Americans’ health care concerns

January 26, 2021

New insulin report highlights how incentives benefit middlemen, harm patients

January 22, 2021

Key facts: The final rebate rule will be a positive change for patients

January 19, 2021

Election insights: Voter priorities in the states

December 17, 2020

Insights from the election: Meeting voters where they are on health care

December 15, 2020

Final rebate rule represents right way to change Medicare

December 1, 2020

Accumulator adjustment programs lead to surprise out-of-pocket costs and nonadherence, analysis finds

November 19, 2020

Deep dive: The issues that drove the 2020 vote

November 13, 2020

Voters want to address the real drivers of health care costs for patients and the system

November 2, 2020

Proposed change to Medicaid line extension definition ignores importance of critical improvements in treatments

October 13, 2020

Study finds middlemen excluded nearly 850 medicines from formularies this year

September 17, 2020

Recent administration actions undermine patient assistance programs

September 16, 2020

Manufacturer cost-sharing assistance programs can save chronically ill patients hundreds to thousands of dollars annually

August 19, 2020

Commercial health plans have increased patients’ out-of-pocket costs by over 50% in some therapeutic areas

August 12, 2020

Commercial health plans transition from copays to coinsurance and deductibles has increased patient out-of-pocket costs

August 6, 2020

Four things to know about the IQVIA “Medicine Spending and Affordability in the U.S.” report

August 5, 2020

New data show commercially insured patients face increasingly high cost sharing for brand medicines

July 30, 2020

Payers subject 80% of new RA and MS patients to utilization management restrictions

July 22, 2020

PhRMA submits comments to CMS on Medicaid proposed rule

July 21, 2020

New rule makes it harder for patients to lower their out-of-pocket costs

May 20, 2020

ICYMI: Patients saved nearly $800,000 out of pocket through innovative contracting arrangements

April 20, 2020

PhRMA comments on HHS proposed rule on manufacturer cost-sharing assistance and accumulator adjustment programs

March 3, 2020

Addressing barriers that inhibit value-based contracts

February 21, 2020

New NHE data: Medicine prices declined, and hospitals were biggest driver of health care spending in 2018

December 6, 2019

New data show how ICER’s value framework could prevent or delay access to treatments for Medicaid patients across the country

November 4, 2019

Guest post: Sharing discounts and rebates is the right thing to do

October 21, 2019

Survey shows out-of-pocket costs top health care concern for voters

October 2, 2019

Four reasons why the radical Pelosi Plan is the wrong approach

September 24, 2019

Hospitals make 9 times more than physicians’ offices on provider-administered medicines

September 10, 2019

Three things to know about the Part D GAO report

August 16, 2019

Four states adopt first-in-the-nation laws to protect patients from surprise insurer practices

July 15, 2019

How the rebate rule would help reduce patients’ out-of-pocket costs

June 3, 2019

Ask About Adherence: OIG proposed rule to reform the rebate system could improve adherence

May 15, 2019

Six policy solutions to help patients afford their insulin

April 9, 2019

Five key facts about the market for insulins

April 1, 2019

OIG proposed rule could help strengthen the Part D market

March 28, 2019

Rebate rule would help ensure seniors with diabetes don’t pay more for their medicine than their insurer

March 25, 2019

New analysis shows 820,000 prescriptions would be in jeopardy if ICER’s value framework is used in Medicaid

March 20, 2019

Stay current on policy making

Sign up for email updates and follow us on social. 

About

Our Agenda

Policy Issues

Resources

Blog

Contact Us

Privacy Policy

Terms of Service

Facebook

Facebook

X

Twitter X

LinkedIn

LinkedIn

Instagram

instagram logo

America's Medicines

PhRMA Foundation

Voters for Cures

Working for Cures

Innovation.org

Please type your email

Success!

You've been added to the list